The nonreceptor tyrosine kinase Fes is implicated in myeloid cells differentiation. It has been observed that its localization can be cytoplasmic, perinuclear, or nuclear. To further characterize this point, we studied Fes subcellular localization in myeloid cell lines (HL60 and K562) and in COS1 cells. Fes was observed in both the nucleus and the cytoplasm of HL60, K562 cells overexpressing Fes and only in the cytoplasm of COS1 cells, suggesting that nuclear localization is cell context dependent. Moreover, in myeloid cells, the treatment with differentiation-inducing agents such as retinoic acid, phorbol esters and vitamin D, is followed by an increase of the oligomeric form of Fes in the nucleus. In fact, oligomerization seems to be necessary for translocation to occur, since Fes mutants missing the coiled-coil domains are not able to form oligomers and fail to localize in the nucleus. The active form of Fes is tyrosine phosphorylated; however, phosphorylation is not required for Fes to localize in the nucleus, since tyrosine kinase inhibitors do not block the translocation process.
Introduction
Signal transducers are in many cases modular proteins (Pawson, 1995; Hunter, 2000) . This consideration confers a new point of view for studying intracellular interactions and mechanisms. The joining of different domains can serve a variety of functions and the lack of one specific module can lead to the loss of a specific activity. p92 c-Fes is a protein, 822 amino acids in length and it is composed by three main regions: a unique aminoterminal region containing two coiled-coil domains (CC1, CC2) responsible for the formation of homo-and eterooligomers (Read et al., 1997; Cheng et al., 1999) , a central SH2 domain able to recognize and bind specific phosphoproteins (Songyang et al., 1994) , a carboxy terminal region bearing an ATP binding site, the kinase domain, able to recognize a specific phosphorylation consensus sequence (Pinna and Ruzzene, 1996) and two sites for tyrosine phosphorylation (Hjermstad et al., 1993) .
The biological role played by p92 c-Fes has been extensively studied in myeloid cells. In this cell context, Fes is associated with the differentiation process (Feldman et al., 1985; Ferrari et al., 1985 Ferrari et al., , 1995 Emilia et al., 1986; Yu et al., 1989) . In fact, hematopoietic stem cells (Care et al., 1994; Phillips et al., 2000) and leukemic blasts with a differentiation block express low levels of the protein, while more differentiated myeloid cells and leukemic blasts, induced to differentiate by treatment with all trans retinoic acid (ATRA), phorbol esters (PMA) or vitamin D (VD), express higher levels of p92 c-Fes (Ferrari et al., 1985; MacDonald et al., 1985) . On the other hand, experiments with antisense oligonucleotides in HL60 cells (M2/M3 type leukemic cells as defined by the FAB and immunophenotypic classification (Bennett et al., 1976; Drexler, 1987) ) clearly showed that after inhibition of Fes mRNA and primary transcript, the mono-machrophagic differentiation induced by treatment with PMA is no longer achievable . Moreover, the treatment of HL60 cells and of M3-type leukemic cells obtained from patients with ATRA pushes them toward apoptosis rather than to granulocytic differentiation (Manfredini et al., 1993; Ferrari et al., 1994) , suggesting a role for p92 c-Fes both in the differentiation and survival pathways. More recently the expression of p92 c-Fes was described in vascular endothelial cells, suggesting an involvement of the protein in the angiogenetic process Haigh et al., 1996) , in embryonic tissues, suggesting an essential role in early development (Hackenmiller and Simon, 2002; Care et al., 1994) and in neuroblastoma cell lines responsive to ATRA (Hovland et al., 2001) .
Although the knowledge about the biological function of Fes has improved, still little is known about the pathways in which p92 c-Fes is involved. Evidence exists that p92 c-Fes is able to activate STAT3 (Nelson et al., 1998) , to interact with BCR via its N-terminal domain (Li and and that gp130, the transducer chain shared by many cytokines, following stimulation, is able to induce tyrosine phosphorylation of Fes determining its activation in hematopoietic cells (Matsuda et al., 1995) . Other reports indicate that cytokine engagement of the IL-4 receptor leads to phosphorylation of p92 c-Fes (Izuhara et al., 1994) and that p92 c-Fes recognizes and phosphorylates a p130 and a p75 in a colony stimulating factor-1 (CSF-1)-dependent macrophage cell line (Areces et al., 1994) . Other possible c-Fes interactions are summarized in literature (Ferrari et al., 1995; Smithgall et al., 1998; Greer, 2002) . Gene targeting experiments in mice have demonstrated that myelopoiesis is not substantially affected by the lack of c-Fes activity or c-Fes (Hackenmiller et al., 2000; Zirngibl et al., 2002) . On the other hand, the Hackenmiller group has recently shown, in a further work, that truncation of c-Fes via gene targeting results in embryonic lethality and hyperproliferation of hematopoietic cells (Hackenmiller and Simon, 2002) .
Another important issue involves the subcellular localization of p92 c-Fes and the way it becomes active. To investigate on this point, we used two myeloid leukemic cell lines: HL60 and K562. The latter are particularly interesting because they do not express endogenous Fes but ectopic expression of this gene has been shown to potentiate myeloid differentiation (Yu et al., 1989) . Recent studies suggest that the active form of Fes is oligomeric and that its unique N-terminal region containing the two coiled-coil domains is required for the oligomerization to occur (Read et al., 1997; Cheng et al., 1999) . Moreover, it has been shown that p92 c-Fes is able to autophosphorylate in trans and that the major site of autophosphorylation maps at Tyr 713 (Hjermstad et al., 1993) . Deletion of this site reduces the catalytic activity of c-Fes toward a model substrate by more than 90% (Hjermstad et al., 1993) . As a whole, these data suggest that to be fully activated p92 c-Fes must be in the oligomeric conformation and, possibly, Tyr 713 must be phosphorylated. At this time it is not clear whether oligomerization is necessary for trans-phosphorylation or rather the opposite: in fact several proteins, such as MAP kinase, require to be phosphorylated to be able to oligomerize (Khokhlatchev et al., 1998) . As far as the subcellular localization of p92 c-Fes is concerned, Haigh et al. examined a number of different cell types by immunofluorescence with a Fes-specific antiserum (Haigh et al., 1996; Zirngibl et al., 2001) . They observed a pattern of perinuclear staining with extensions toward the plasma membrane. Using Cos-1 cells transfected with GFP-Fes they colocalized Fes and g-adaptin, a protein associated with the trans-Golgi compartment. In contrast to these results, using cell fractionation techniques, Yates et al. reported nuclear localization of Fes both in primary neutrophils and in the human leukemia cell line HL60 (Yates et al., 1995) .
In the present report we provide evidence that Fes localization is cell context dependent, since nuclear translocation is achieved only in myeloid cells and not in Cos1 cells. We also show that the treatment of K562 cells overexpressing Fes and of HL60 cells with ATRA, VD or PMA induces an increase of p92 c-Fes abundance in the nucleus both in the monomeric and in the oligomeric form and that deletion of either CC1 or CC2 impairs the process of nuclear translocation. Moreover, our data show that the phosphorylated form of p92 c-Fes is predominant in the nuclear compartment. As a whole these data allow to draw a model representing the mechanism through which Fes becomes activated in myeloid cells upon induction of differentiation, without excluding a role for this protein in the cytoplasmic compartment as well. At this point, the mechanism allowing p92 c-Fes to translocate to the nucleus remains to be clarified.
Results

Subcellular localization of p92 c-Fes in response to differentiation induction in myeloid cells
To asses whether the subcellular localization of p92 c-Fes is influenced by the induction of differentiation, we designed a construct (pEGFP-FES) ( , we carried out Western blot analysis on cytoplasmic and nuclear extracts of HL60 cells before and after treatment with ATRA, VD, and PMA. The results are superimposable to those obtained in pCMV-FLAG-FES transfected K562 and are reported in Figure 4a where p92 c-Fes is evident both in the nuclear and in the cytoplasmic compartments and the treatment with the differentiation-inducing agents determines an increase in its nuclear localization (Figure 4a, lanes 1-4) . Panels b and c of the same figure are the controls as described in Figure 3 . 
EGFP-FES distribution in COS1 cells
To determine whether the subcellular localization of p92 c-Fes is cell context dependent, we transiently transfected COS1 cells with pEGFP-FES. Fluorescence microscopy shows that in untreated cells, p92 c-Fes is localized exclusively in the cytoplasm ( Figure 5 , panel a) and, particularly, in the perinuclear area as it had been already described (Haigh et al., 1996; Zirngibl et al., 2001) . 
Identification and subcellular localization of a novel spliced isoform of p92 c-Fes
The RT-PCR amplification of c-fes cDNA deriving from HL60 mRNA necessary for developing the EGFP-FES construct allowed us to identify a novel splicing isoform of c-fes, which lacks both exon 7 and exon 11 (FES-D7D11) showing no frame shift in its sequence. We therefore developed an EGFP fusion construct containing the splicing variant of c-fes cDNA ( D7D11 could be detected. Since exon 11 encodes a portion of the SH2 domain and, based on an extensive computational analysis, both exons 7 and 11 lack nuclear localization signals, we were prompted to investigate whether the nuclear translocation of p92 c-Fes could depend on the interaction of the SH2 domain with a putative chaperon (Nair et al., 1996) . At that purpose, we developed an EGFP fusion construct encoding c-fes SH2 domain (Figure 1 , a3) and checked its expression in K562 cells. Figure 6c shows the LSCM imaging of K562 cells transfected with pEGFP-FES-SH2. Interestingly, also this protein fails to translocate to the nucleus in K562 cells upon induction of differentiation suggesting that the SH2 domain is possibly required but not sufficient for c-Fes nuclear translocation ( Figure 6f ).
Subcellular localization of p92 c-Fes NH 2 -terminal domain and of its deletion mutants
Considering that exon 7 encodes a portion of p92 c-Fes located between the two coiled-coil domains, that the process of nuclear translocation probably deals with Fes activation and that evidence exists in literature that CC1 and CC2 are invloved in Fes activation (Read et al., 1997; Cheng et al., 1999; Smithgall et al., 1998) , we investigated whether the coiled-coil domains of p92 We treated these cells with the differentiation-inducing agents and checked them at confocal microscopy. The results are shown in Figure 8 : panel a shows transfected K562 cells nontreated with differentiation inducing agents, the fluorescence is cytoplasmic; panel b, c, and d are the same cells treated, respectively, with ATRA, PMA, and VD, the fluorescence becomes predominantly nuclear while a decrease in the cytoplasmic fraction of Fes can be detected. We believe that Fes localization is strongly influenced by the treatment with the differentiation-inducing agents, hence a possible solution to the controversy existing with the paper of Haigh et al. where the treatment with these agents was not performed. It is important to point out that the Nterminal mutants that do not move to the nucleus (Western blot, Figure 7a , lanes 2-4 and 8-10), retain this inability even after treatment with the differentiation inducing agents (data not shown). As a whole, these results suggest that the coiled-coil domains are necessary to achieve nuclear localization.
Subcellular localization of p92 c-Fes oligomers
Since it has been described that p92 c-Fes is able to form homo-oligomers through the interaction of its Figure 7 Panel a of the figure shows the autoradiography of the Western blot performed on nuclear extracts (lanes 1-6) and on cytoplasmic extracts (lanes 7-12) of K562 cells transfected with the pCMV-FLAG-FES (lanes 6 and 12) and with the deletion constructs pCMV-CC1 (lanes 2 and 8), pCMV-DCC2 (lanes 3 and 9), pCMV-DCC1 (lanes 4 and 10), pCMV-N-TER-FES (lanes 5 and 11). The experiment shows that the proteins expressed by a construct missing the CC1 or the CC2 domain are not able to translocate to the nucleus, while the constructs expressing the whole protein or the N-terminal domain are present in the nucleus. coiled-coil domains and that it has been hypothesized that the oligomers are the active form of p92 c-Fes (Read et al., 1997; Smithgall et al., 1998; Cheng et al., 1999) , we investigated whether oligomerization is a cytoplasmic or a nuclear event and whether it is required for translocation. To do so, we treated HL60-FLAG-FES cells with the crosslinking agent BS3 and we checked the formation of oligomers in cytoplasmic and nuclear extracts. Figure 9 panel a shows a Western blot of HL60-FLAG-FES treated with 2 mm BS3 (lanes 1-2) and with BS3 and ATRA (lanes 3-4). Lanes 1 and 3 refer to cytoplasmic extracts and lanes 2 and 4 to nuclear extracts. Lanes 5-8 show the same samples not treated with BS3. The experiment shows that the oligomeric form of Fes is nuclear and that the treatment with ATRA induces an increase of both the monomeric and the oligomeric forms of p92 c-Fes in the nucleus. Figure 9 panel b shows a Western blot of cytoplasmic and nuclear extracts of K562 expressing p92 DCC1 respectively (lanes 1 and 3) and p92 DCC2 (lanes 2 and 4) . The autoradiography shows that the forms of c-Fes missing the coiled-coil domains are detected in the cytoplasmic compartment ( Figure 9b , lanes 1, 2) and fail to form oligomers and translocate to the nucleus (Figure 9b , lanes 3, 4). As a whole, these data confirm that the coiled-coil domains are required for the formation of Fes oligomers and, interestingly, that the formation of oligomers is highly related to the nuclear localization. The presence of monomeric p92 c-Fes in the nuclei of HL60-FLAG-FES cells (Figure 9 , panel a) might be explained by a dynamic balance between monomers and oligomers in this compartment. In order to find a correlation between the formation of the oligomers, the process of nuclear translocation and ATRA-induced differentiation we analysed by Western blot cytoplasmic and nuclear extracts of HL60 cells both untreated and treated with ATRA from 6 to 48 h (Figure 10 ). Again, Fes expression together with the formation of oligomers is increased by ATRA treatment in the nuclear compartment ( Figure 10, lanes 1-4) . No oligomeric Fes is detected at the cytoplasmic level (Figure 10 , lanes 5-8) while a decisive step occurs between 6 and 24 h when, at nuclear level, oligomers are strongly induced suggesting a correlation between amount of oligomers and this period of differentiation.
Correlation between tyrosine phosphorylation and the formation of oligomers
Since Fes tyrosine phosphorylation is a reflection of the activated state of the enzyme (Hjermstad et al., 1993) , we looked for differences in phosphorylation between nuclear and cytoplasmic Fes (Figure 3, panel b) . We observed that p92 c-Fes is phosphorylated mainly in the nuclear compartment and that phosphorylation rises following the treatment with the differentiationinducing agents. As a consequence, we tried to correlate the nuclear translocation of p92 c-Fes with tyrosine phosphorylation since there are many examples of proteins that require to be phosphorylated in order to translocate to the nucleus (Khokhlatchev et al., 1998) . To do so, pEGFP-FES stably transfected K562 cells were treated with 200 mm genistein, a strong inhibitor of tyrosine kinases, and then induced to differentiate with ATRA, VD, or PMA. Results were obtained by LSCM. No effects on nuclear translocation of p92 c-Fes were found following treatment with genistein (data not shown), indicating that tyrosine phosphorylation is not required for nuclear translocation and allowing to hypothesize that the observed phosphorylation is mainly a nuclear event that depends on the formation of oligomers. To strengthen this observation we performed Western blot analysis on HL60-FLAG-FES cells after treatment with both genistein and the crosslinking agent BS3. The results are shown in Figure 11a , where lane 1 represents the cytoplasmic extract and lane 2 the nuclear fraction. No impairment in both oligomerization and nuclear localization could be detected. Panel b is a control experiment showing that genistein is able to inhibit Fes phosphorylation.
Discussion
The data presented in this report confirm that p92 c-Fes , as previously described by Yates et al. (1995) , can be localized in the nucleus. The process of nuclear translocation appears to be cell context dependent since transfection experiments performed in COS-1 (Haigh et al., 1996) , HL60 and K562 cells clearly showed that Fes translocation takes place only in the myeloid lineage and in particular, following treatment with ATRA, PMA, or VD. Interestingly, K562 cells that do not express endogenous Fes, gain the ability to differentiate following expression of c-Fes (Yu et al., 1989) , therefore they are a suitable cell context for studying c-Fes role and localization. On the other hand, COS1 cells, a fibroblast-like kidney-derived cell line, do not express endogenous Fes and possibly do not even express the lineage-specific factors which are required for Fes translocation. At first glance, our report may appear to be in contrast with the work of Haigh et al. about Fes localization (Haigh et al., 1996) , but a careful evaluation of the data shown in both works suggests rather the opposite. In fact, Haigh et al. state that they do detect a small degree of diffuse intranuclear immunofluorescence with some anti-Fps/Fes antiserum in myeloid, endothelial and neuronal cells, although in Cos-1 cells an EGFP-Fes fusion protein could be detected just in the cytoplasm and especially in the perinuclear area. We repeated the Cos-1 experiment and obtained a pattern of Fes distribution superimposable to what was observed by Haigh et al. Then we expressed the same EGFP-FES fusion construct in K562 cells that we successively treated or not with differentiation-inducing agents. This experiment allowed an important observation: in the untreated cells the fluorescence is detectable mainly in the cytoplasmic compartment and almost absent in the nucleus, in agreement with the previous work, but K562 cells treated with ATRA, PMA, or VD show very high Figure 10 Western blot of nuclear (lanes 1-4) and cytoplasmic (lanes 5-8) extracts deriving from HL60 cells untreated (lanes 1 and 5) and treated with ATRA for 6, 24 and 48 h (lanes 2-4 and 6-8). All the samples were treated with BS3. The experiment shows an increase of both c-Fes monomers and oligomers only in the nuclear compartment following ATRA treatment Detection of p92 c-Fes oligomers in the nucleus E Tagliafico et al nuclear fluorescence, suggesting that this kind of stimulus is pivotal for p92 c-Fes nuclear translocation. It is also worth mentioning that our experiments showed that there is a different sensitivity between Western blot on purified nuclear extracts and confocal microscopy. In fact, the nuclear fractions are concentrated during the purification procedure: hence, the evidence in Western blot of detectable levels of nuclear full-length Fes or NH 2 -terminal Fes in untreated cells is not surprising, whereas no Fes fluorescence is detectable in nuclei by LSCM.
Since c-Fes plays an important role in the differentiation of normal cells and leukemic blasts and it is known as well that its expression rises during cell maturation (Ferrari et al., 1985) , we tried to correlate nuclear translocation and differentiation by treating HL60 cells and K562 cells transfected with pCMV-FLAG-FES, with differentiation-inducing agents such as ATRA, VD, and PMA. After the treatment, we performed confocal microscopy and Western blot experiments to unequivocally establish the subcellular distribution of Fes. We showed that p92 c-Fes is present in both the cytoplasm and in the nucleus, but that the treatment with the different inducers determines an increase in p92 c-Fes abundance in the nucleus. Whether this phenomenon is due to an increase in Fes expression or to the stabilization of the protein is not clear.
During the process of c-Fes cDNA cloning by RT-PCR, we found a previously undescribed splicing form. The spliced mRNA, which we called FES-D7D11, misses both exons 7 and 11. Exon 7 encodes an aminoterminal portion of p92 c-Fes located between the two coiled-coil domains, while exon 11 encodes a portion of the SH2 domain. We verified by confocal microscopy whether this isoform was able to translocate to the nucleus. The experiments show that this is not the case. We then explored whether the SH2 domain, the region between the two coiled-coil domains and the coiled-coil domains themselves, might play a role in the process of nuclear translocation. At that purpose, we developed several constructs to express in K562 cells mutants of p92 c-Fes missing CC1 (DCC1), CC2 (DCC2), and other mutants expressing only the SH2 domain or the CC1 domain Only the mutants carrying the entire aminoterminal domain are able to translocate to the nucleus. It follows that both the coiled-coil domains are necessary for Fes to translocate and that they must be in a specific spatial conformation, since the removal of the portion of p92 cFes between the two coiled-coil domains (D7D11) impairs the translocation. To check whether p92 c-Fes oligomerization (Read et al., 1997; Smithgall et al., 1998; Cheng et al., 1999) is somehow related to the event of nuclear translocation we performed Western blot experiments on HL60 cells overexpressing c-Fes and on K562 cells expressing mutants missing CC1 and CC2. These experiments showed that Fes oligomers are localized in the nucleus and that the deletion of the coiled-coil domains prevents both oligomerization and nuclear translocation, thus confirming the key role of the coiledcoil domains in this process.
We then looked whether phosphorylation is involved in Fes translocation. This hypothesis was tested keeping in mind that p92 c-Fes is able to autophosphorylate in trans (Rogers et al., 1996) and that several papers describe a common mechanism for different proteins to achieve nuclear translocation. It has been shown, for instance, that phosphorylation of MAP kinase is a prerequisite for dimerization and nuclear translocation (Khokhlatchev et al., 1998) . We first carried out an immunoprecipitation experiment to verify whether p92 cFes is predominantly phosphorylated in the cytoplasmic or in the nuclear compartment. Our results indicate that the phosphorylation is mainly nuclear. Then we treated K562 cells stably transfected with the pCMV-FLAG-FES vector with genistein, a tyrosine kinase inhibitor, and we verified whether there was a perturbation on nuclear translocation: no effect of genistein was detected confirming that phosphorylation is not required for nuclear localization. Moreover, we analysed on Western blot cytoplasmic and nuclear extracts of HL60-FLAG-FES cells treated with both genistein and BS3 to check whether the inhibition of tyrosine kinases impairs oligomerization. In our model, we did not observe any perturbation both in the formation of the oligomers and in the translocation process suggesting that trans phosphorylation is not a pre-required event but rather the result of oligomerization and nuclear localization.
As a whole this work suggests that Fes may play a role at nuclear level, where only a few tyrosine kinases have been detected so far (Hazan et al., 1993; Cance et al., 1994; Sawyers et al., 1994; Pendergast, 1996) . Upon induction of differentiation in myeloid cells, p92 cFes is not only increased in the nuclear compartment but it is also phosphorylated and mainly in an oligomeric conformation. It is interesting to underline that timecourse experiments show a high degree of correlation between the amount of oligomers in the nucleus and the ATRA-induced differentiation process. We believe that this behavior is strictly context dependent and that in other cellular environments alternative isoforms of Fes can be expressed and therefore may or may not translocate to the nucleus. Our data put emphasis on the modular structure of p92 c-Fes . The expression of specific modules is required for Fes nuclear activation, and as an evidence we show the data about the mutants missing the coiled-coil domains and the alternatively spliced form missing exons 7 and 11. Since Fes is not only expressed in myeloid cells, that is vascular endothelial cells, where it is involved in angiogenetic processes (Haigh et al., 1996) or in lymphoma cell lines, where an isoform of 16 kDa has been detected (Jucker et al., 1992) , it would be interesting to verify whether oligomerization and nuclear translocation are common processes for these tissues as well and, if not, it would be interesting to study the mechanisms underlying the different roles of p92 c-Fes .
Materials and methods
Cell cultures
K562 (myelo-erythroid precursors), and HL60 (myeloblasts) cell lines were obtained from ATCC and cultured, as already described (Manfredini et al., 1999) , in RPMI 1640 medium (Life Technologies Inc., Gaithersburg, MD, USA), supplemented with 10% fetal bovine serum (FBS) (Life Technologies Inc., Gaithersburg, MD, USA) and 2 mm l-glutamine (Life Technologies Inc., Gaithersburg, MD, USA). Differentiation was induced by treatment with 10 À6 m ATRA (Sigma Chemical Co., St Louis, MO, USA) or with 10 -7 m VD (HoffmanLaroche, Basel, Switzerland) or with 100 nm PMA (Sigma Chemical Co., St Louis, MO, USA) by treating the cells for 6, 12, 24, and 48 h. Differentiation was monitored by May Grumwald Giemsa (MGG) staining, immunophenotypic analysis with phycoerythrin-conjugated mouse anti-human CD38, CD11c, CD11b, CD14 monoclonal antibodies (Becton Dickinson Immuno-cytochemistry Systems, San Jose, CA, USA), performed by flow cytometry as already described . COS1 cells (African green monkey cells) were cultured in Dulbecco's modified minimal essential medium (DMEM) supplemented with 10% FBS (Life Technologies Inc., Gaithersburg, MD, USA) and 2 mm l-glutamine (Life Technologies Inc., Gaithersburg, MD, USA). The same cells were stimulated, respectively, with 10 -6 m ATRA (Sigma Chemical Co., St Louis, MO, USA), 100 nm PMA (Sigma Chemical Co., St Louis, MO, USA) or 10 -7 m VD (HoffmanLaroche, Basel, Switzerland). pLfesSN infected HL60 cells (HL60-FLAG-FES, see also retroviral infection) were cultured and treated as described for HL60 cells. Genistein (Sigma Chemical Co., St Louis, MO, USA) was used at a concentration of 200 mm by treating the cells for 6 h in the presence of serum.
Plasmids
All the vectors containing the different Fes functional domains are summarized in Figure 1 . For LSCM experiments, we designed four fusion constructs: the first expressing the fulllength coding region of c-fes cDNA fused in frame to the fluorescent protein encoded by the pEGFP-C3 plasmid (Clontech Laboratories Inc., Palo Alto, CA, USA) (pEGFP-FES, Figure 1, a1) , the second encoding a c-Fes splicing form missing exons 7 and 11 (pEGFP-FES-D7D11, Figure 1, a2) , the third encoding the SH2 domain of c-Fes (pEGFP-FES-SH2, Figure 1 , a3) and the fourth encoding the aminoterminal domain of c-Fes (CC1 and CC2) fused in frame to the green fluorescent protein (pEGFP-N-TER-FES, Figure 1, a4) . pEGFP-C3 encodes a redshifted variant wild-type GFP Detection of p92 c-Fes oligomers in the nucleus E Tagliafico et al (Chalfie et al., 1994; Inouye and Tsuji, 1994; Haas et al., 1996) . The different c-Fes domains listed above were all cloned in the EcoRI site of pEGFP-C3. The expression vectors used for cell transfection and Western blot analysis were originated by the following procedure: the pCMV vector was derived from pEGFP-C3 by excision of the EGFP box by NheI-BgIII digestion. The full length c-Fes cDNA was obtained by RT-PCR using a direct primer (5 0 -TTT-TTA-AGC-TTA-GAT-CTC-GCC-ACC-ATG-GAC-TAC-AAG-GAC-GAC-GAT-GAC-AAG-GGC-TTC-TCT-TCC-GAG-CTG-TGC-AAG-CCC-CCA-GG- 3 
Cell transfection
Cultures were maintained in RPMI 1640 medium with 5% FBS as already described . Cells (2.5 Â 10 7 ) were transfected by electroporation with 30 mg of plasmid. Electroporation was performed at 250 V, 960 mF. Cells were then washed three times with RPMI medium (GIBCO-Invitrogen Corporation, Invitrogen Ltd, Paisley, UK). Transfected cells were then cultured in RPMI medium containing 5% FCS. pEGFP-transfected cells were used in all the transfection experiments to evaluate the transfection efficiency by flow cytometry. The cells stably transfected with the different pEGFP constructs (Figure 1, a1-4) were selected in G418 (1 mg/ml for 20 days). Cos1 cells were transiently transfected with the pEGFP-FES vector using LipofectA-MINE Plus reagents (GIBCO-Invitrogen Corporation, Invitrogen Ltd, Paisley, UK) with 1 mg of DNA per 35 mm dish according to the protocol provided by the company. At 24 h after transfection the medium was changed and the treatments with the differentiating agents were started. Different 35 mm dishes were stimulated, respectively, with 10 À6 m ATRA, 64 nm PMA and 10 À7 m VD. Following a 24 h incubation with the differentiating agents, expression of the transgene was checked by fluorescence microscopy.
Retroviral infection
A retroviral vector containing c-Fes full-length cDNA (pLfesSN) was developed as follows: the c- (Miller and Rosman, 1989 ) (Clontech Laboratories Inc., Palo Alto, CA, USA). All the constructs were sequenced on ABI Prism 377 DNA sequencer.
The packaging of the pLfesSN vector was performed by means of the transinfection procedure by using the ecotropic GP+E86 packaging cell line and amphotropic GP+ env Am12 packaging cell line as already described . Supernatant of the amphotropic GP+ env Am12 was then used to transduce HL60 cells as already described . c-Fes transduced HL60 cells (HL60-FLAG-FES), selected in G418, were analysed for Fes expression by Western blot analysis. HL60-FLAG-FES show higher c-Fes expression than normal HL60 cells.
Laser scanning confocal microscopy
Cells (20-30 Â 10 4 ) from the different samples were cytocentrifugated at 400 r.p.m for 5 0 on Cytospin 3 cytocentrifuge (Shandon Limited, Astmoor, England). The cytospins were air-dried and immediately subjected to laser confocal analysis.
Confocal images were acquired by laser scanning by SCANWARE 5.0 software with a confocal microscope Leica TCS4D installed on a LEICA IRBE inverted microscope equipped with a 20 Â dry, a 40 Â oil and a 63 Â oil objective lens. We utilized a light source (Ar-Kr laser), filters and a photomultiplier tube (PMT) suitable for EGFP excitation (488 nm) and detection (507 nm). Typically, between 20 and 25 optical sections through focus (Z step 0.2 mm) were taken for each image. The resulting images were processed in Adobe Photoshop 5.0 software for colour channel analysis and figure assembly.
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Nuclear and cytoplasmic extracts preparation
Nuclear extracts of HL60 and K562 cells, before and after treatment with ATRA, VD, or PMA, were obtained as already described (Dignam et al., 1983) with minor modifications . Briefly the cells were centrifuged, washed in phosphate-buffered saline (PBS) and resuspended in 5 volumes of 0.3 m sucrose, 10 mm HEPES-KOH pH 7.9, 10 mm KCl, 1.5 mm MgCl 2 , 0.1 mm EGTA, 0.5 mm dithiothreitol (DTT), 1 Â Completet protease Inhibitor cocktail (Roche Biochemicals, USA) 1 mm Na 2 MoO 4 , 1 mm Na 3 VO 4 . Cells were then lysed in a Dounce homogenizer by 10 strokes of the pestle, followed by two strokes in the presence of 0.15% Nonidet P40. Lysis was monitored by phase-contrast microscopy. The homogenate was then centrifuged in order to separate nuclei from the supernatant. The supernatant was clarified by centrifugation for 40 min at 100 000 Â g and stored as cytoplasmic extract. The nuclei were washed twice in the same buffer without NP-40, recovered by centrifugation at 1200 g for 10 min and then resuspended in 10 mm HEPES-KOH pH 7.9, 400 mm NaCl, 1.5 mm MgCl 2 , 0.1 mm EGTA, 0.5 mm DTT, 5% glycerol, 1 Â Completet protease Inhibitor cocktail (Roche Biochemicals, USA) 1 mm Na 2 MoO 4 1 mm Na 3 VO 4 . After four strokes in Dounce homogenizer, the homogenate was stirred for 30 min at 41C followed by centrifugation for 40 min at 100 000 Â g. The nuclear and cytoplasmic extracts were finally dialyzed overnight at 41C with 100 vol. of Tris-buffered saline (TBS) (50 mm Tris HCl, 159 mm NaCl, pH 7.4) supplemented with 1 Â Completet protease inhibitor cocktail (Roche Biochemicals, USA) 1 mm Na 2 MoO 4 1 mm Na 3 VO 4 and stored at À801C. Protein concentration was evaluated by the Bradford method.
Immunoprecipitation
Cytoplasmic or nuclear extracts (500 mg of protein) were immunoprecipitated for 2 h at room temperature with 10 ml (gel bed) of anti FLAG s M2 affinity gel (Sigma Chemical Co., St. Louis, MO, USA) in 200 ml of TBS buffer supplemented with 1 Â Completet protease Inhibitor cocktail (Roche Biochemicals, USA) 1 mm Na 2 MoO 4 1 mm Na 3 VO 4 , 1% Triton X-100. The gel bed was washed five times in the same buffer and resuspended in 50 mm Tris pH 6.8, 5% bmercaptoethanol, 2% SDS, 0.1% bromophenol blue, 10% glycerol. The immunoprecipitates were resolved by SDS-PAGE and transferred on to a nitrocellulose filter.
Western blotting analysis and crosslinking experiments
Western blot analysis was performed as described (Burnette, 1981) with modifications. Briefly: 50 mg of nuclear or cytoplasmic extracts of each sample were dissolved in 1 Â reducing loading buffer (50 mm Tris pH 6.8, 5% b-mercaptoethanol, 2% SDS, 0.1% bromophenol blue, 10% glycerol), loaded onto 7.5-10% SDS-PAGE and electrophoresed in TGS buffer (25 mm Tris pH 8.3, 250 mm glycine, 0.1% SDS). The separated proteins were transferred at 41C on to a nitrocellulose membrane by electroblotting procedure in TGM buffer (25 mm Tris pH 8.3, 250 mm glycine, 20% methanol) for 2 h at 1 A. In order to monitor the electroblotting efficiency the membrane was stained in 0.2% Ponceau S, 0.3% trichloroacetic acid (TCA) and destained in 0.3% TCA. Membranes were preblocked in Tris-buffered saline-Tween-20 (TBST) (10 mm Tris pH 8, 150 mm NaCl, 0.1% Tween 20), supplemented with 5 mg/ml goat serum for 1 h at room temperature and incubated in the same buffer for 1 h at room temperature with a 1 : 200 dilution of anti v-fes monoclonal antibody (Ab1, Oncogene Research, Calbiochem, San Diego, CA, USA) or with a 1 : 500 dilution of antiphosphotyrosine monoclonal antibody (PY99, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) or with a 1 : 10 000 dilution of anti-FLAG s M2 monoclonal antibody (Sigma Chemical Co., St Louis, MO, USA). Membranes were washed twice in TBST and then incubated with the indicated goat-secondary antibody horseradish peroxidase (HRP)-conjugated (1 : 50 000) (40 min at r.t.) in TBST/serum solution. After several washes in TBST, the detection was carried out by incubation for 3 min in SuperSignal s West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA) and autoradiography. b-actin, NF-Y and golgin Western blots were performed as described above by using, respectively, a rabbit IgG anti-b-actin (Sigma Chemical Co., St Louis, MO, USA) and a secondary antibody antirabbit HRP (Amersham Pharmacia Biotech, UK); an antibody anti-NF-Y (Mantovani et al., 1992 ) with a secondary antimouse IgG; an anti-human golgin-97 mouse monoclonal antibody (Molecular Probes, OR, USA) with a secondary ab anti-mouse IgG. In the experiments with Bis(sulfosuccinimidyl)suberate (BS3) (Pierce, Rockford, IL, USA), the proteic extracts were crosslinked with the agent diluted to 2 mm for 1 h at room temperature and then processed with the standard procedure.
